[Proteins in rheumatology and clinical immunology]
Publisher DOI
PubMed ID
22045522
Abstract
Twelve years ago the tumour necrosis factor (TNF) inhibitors revolutionised the therapy of rheumatoid arthritis and other inflammatory rheumatic diseases. Today, in addition to anti-cytokine strategies, immunosuppressive biologicals have been developed that delete B-lymphocytes or inhibit the activation of T-lymphocytes. The spectrum of indications for these protein drugs will broaden substantially in the near future and will likely include also diseases with orphan status (incidence below 1:10'000). Used in the right indication and with knowledge of molecular effects as well as clinical adverse effects these new drugs do not appear to be more dangerous than conventional disease modifying agents (DMARDs).
Date Issued
2011
Publication Type
Article
Language(s)
de
Additional Credits
Journal
Therapeutische Umschau
Publisher
Huber
ISSN
0040-5930
Access(Rights)
metadata.only